Cross‐Sectional Analysis of Metabolic Tumor Burden Detected by F‐18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer
Cancer Medicine · 2025-08 · 14 (16)
DOI: 10.1002/cam4.71049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 18.08.2025. Verfasst von Recep Halit Tokac und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Ege University Faculty of Medicine, Izmir, Turkey. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Positron Emission Tomography Computed Tomography, Breast Neoplasms, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This study investigated the relationship between circulating tumor DNA (ctDNA) parameters and metabolic parameters from FDG PET/CT in advanced breast cancer (ABC) patients.
Methods
In this retrospective single‐center study, 47 ABC patients who underwent both liquid biopsy and FDG PET/CT were analyzed.
Results
Results showed that 27 patients (57.4%) had detectable ctDNA. Patients with detectable ctDNA demonstrated significantly higher whole‐body metabolic tumor volume (WB‐MTV) ( p = 0.002) and whole‐body total lesion glycolysis (WB‐TLG) ( p = 0.006) compared to those without ctDNA, while no significant difference was found in SUVmax or SUVmean. A moderate correlation was observed between variant allele frequency (VAF) values and metabolic parameters: maximum VAF correlated with SUVmax, WB‐MTV, and WB‐TLG ( r = 0.407, p = 0.005; r = 0.457, p = 0.001; r = 0.415, p = 0.004, respectively). Mean VAF correlated with SUVmax, WB‐MTV, and WB‐TLG ( r = 0.406, p = 0.005; r = 0.446, p = 0.002; r = 0.404, p = 0.005, respectively). The total VAF correlated with SUVmax, WB‐MTV, and WB‐TLG ( r = 0.394, p = 0.006; r = 0.465, p = 0.001; r = 0.430, p = 0.003, respectively). When excluding patients without detectable ctDNA, the correlation between VAF values and WB‐MTV, WB‐TLG disappeared, while the correlation with SUVmax persisted. Total alteration number in ctDNA showed a moderate correlation with WB‐MTV and WB‐TLG ( r = 0.563, p < 0.001; r = 0.459, p = 0.001, respectively). Correlation with WB‐MTV remained significant when excluding patients without detectable ctDNA ( r = 0.500, p = 0.008).
Conclusions
These findings suggest that metabolic tumor burden correlates with ctDNA detection and characteristics, potentially offering complementary information for disease monitoring, treatment selection, and response assessment in ABC. The combined use of these parameters may improve prognostic evaluation and guide personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Ege University Faculty of Medicine, Izmir, Turkey.
- Department of Medical Genetics, Ege University Faculty of Medicine, Izmir, Turkey.
ORCID-Profile: Recep Halit Tokac
Zitieren
APA
Tokac, R. H., Tokac, E. C. B., Yararbas, U., Aykut, A., Durmaz, A., Akin, H., & Argon, A. M. (2025). Cross‐Sectional Analysis of Metabolic Tumor Burden Detected by F‐18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer. Cancer Medicine, 14(16). https://doi.org/10.1002/cam4.71049
Vancouver
Tokac RH, Tokac ECB, Yararbas U, Aykut A, Durmaz A, Akin H, et al. Cross‐Sectional Analysis of Metabolic Tumor Burden Detected by F‐18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer. Cancer Medicine. 2025;14(16). doi:10.1002/cam4.71049
BibTeX
@article{Tokac2025,
author = {Tokac, Recep Halit and Tokac, Ekin Cemre Bayram and Yararbas, Ulkem and Aykut, Ayca and Durmaz, Asude and Akin, Haluk and Argon, Aziz Murat},
title = {Cross‐Sectional Analysis of Metabolic Tumor Burden Detected by F‐18 FDG PET/CT and Circulating Tumor DNA in Advanced Breast Cancer},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {16},
doi = {10.1002/cam4.71049}
}
EUVIMED